Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,559,445 | 3,699,259 | 12,150,770 | 9,011,120 | 5,733,256 |
| Depreciation Amortization | 1,696,824 | 424,278 | 1,366,768 | 937,466 | 569,206 |
| Accounts receivable | N/A | N/A | -2,063,292 | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | 1,454,759 | N/A | N/A |
| Other Working Capital | 35,931 | -1,288,851 | 2,903,710 | -374,052 | -2,079,149 |
| Other Operating Activity | 1,060,893 | -750,568 | 725 | 4,931,586 | 4,307,612 |
| Operating Cash Flow | $9,353,093 | $2,084,118 | $15,813,440 | $14,506,120 | $8,530,925 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 890,620 | 1,889,888 | -690,862 | 816,578 | 493,964 |
| PPE Investments | -2,733,619 | -1,233,814 | -3,747,031 | -2,394,254 | -1,544,423 |
| Net Acquisitions | -96,392 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -4,618 | -2,184 | -39,349 | -1,801,786 | -1,097,211 |
| Sale Of Investment | N/A | N/A | 4,792 | 4,818 | 4,821 |
| Purchase Sale Intangibles | -476,623 | -77,896 | -1,900,668 | -884,906 | -184,817 |
| Other Investing Activity | -476,624 | -77,896 | -1,900,668 | -884,906 | -184,816 |
| Investing Cash Flow | $-2,420,633 | $575,994 | $-6,373,118 | $-4,259,550 | $-2,327,665 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 4,980,226 | N/A | N/A | N/A | N/A |
| Debt Repayment | -774,891 | -46,155 | -213,008 | -162,352 | -124,331 |
| Common Stock Repurchased | -1,484,125 | -412,922 | -4,344,965 | -2,943,798 | -2,048,614 |
| Dividend Paid | -4,120,775 | -4,157,899 | -4,612,568 | -4,637,982 | -2,679,036 |
| Other Financing Activity | -1 | 775,757 | -1 | 0 | 0 |
| Financing Cash Flow | $-1,399,566 | $-3,841,219 | $-9,170,542 | $-7,744,132 | $-4,851,981 |
| Exchange Rate Effect | 12,410 | 6,406 | -17,279 | 13,140 | -47,921 |
| Beginning Cash Position | 2,076,766 | 2,095,475 | 1,837,216 | 1,847,338 | 1,848,603 |
| End Cash Position | 7,622,070 | 920,774 | 2,089,719 | 4,362,918 | 3,151,961 |
| Net Cash Flow | $5,545,305 | $-1,174,701 | $252,503 | $2,515,580 | $1,303,358 |
| Free Cash Flow | |||||
| Operating Cash Flow | 9,353,093 | 2,084,118 | 15,813,440 | 14,506,120 | 8,530,925 |
| Capital Expenditure | -2,733,619 | -1,233,814 | -3,747,031 | -2,394,254 | -1,544,423 |
| Free Cash Flow | 6,619,474 | 850,304 | 12,066,409 | 12,111,866 | 6,986,502 |